Violet 405 nm light: A novel therapeutic agent against β‐lactam‐resistant <i>Escherichia coli</i>

Rhodes, Nathaniel L.R.; Presa, Martin de la; Barneck, Mitchell D.; Poursaid, Ahrash E.; Firpo, Matthew A.; Langell, John T.

doi:10.1002/lsm.22457

Cited by 14 publications

(10 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The abundance of porphyrins generated in microbial cells is the reason behind the more susceptibility of all six representative microbes to 405 nm aBL irradiation than 470 nm, in agreement with the previous study showing that foodborne pathogens Lactobacillus plantarum , S aureus and Vibrio parahaemolyticus were all more susceptible to 405 nm than 460 nm or 520 nm light irradiation . Apart from the six microbes tested, Klebsiella pneumoniae and Escherichia coli were also commonly detected in contaminated PLT concentrates and particularly sensitive to 405 nm aBL reported in the previous studies .…”

Section: Discussionmentioning

confidence: 84%

Antimicrobial blue light for decontamination of platelets during storage

Lü

et al. 2019

Journal of Biophotonics

View full text Add to dashboard Cite

Platelet (PLT) storage is currently limited to 5 days in clinics in the United States, in part, due to an increasing risk for microbial contamination over time. In light of well‐documented antimicrobial activity of blue light (405‐470 nm), we investigated potentials to decontaminate microbes during PLT storage by antimicrobial blue light (aBL). We found that PLTs produced no detectable levels of porphyrins or their derivatives, the chromophores that specifically absorb blue light, in marked contrast to microbes that generated porphyrins abundantly. The difference formed a basis with which aBL selectively inactivated contaminated microbes prior to and during the storage, without incurring any harm to PLTs. In accordance with this, when contamination with representative microbes was simulated in PLT concentrates supplemented with 65% of PLT additive solution in a standard storage bag, all “contaminated” microbes tested were completely inactivated after exposure of the bag to 405 nm aBL at 75 J/cm2 only once. While killing microbes efficiently, this dose of aBL irradiation exerted no adverse effects on the viability, activation or aggregation of PLTs ex vivo and could be used repeatedly during PLT storage. PLT survival in vivo was also unaltered by aBL irradiation after infusion of aBL‐irradiated mouse PLTs into mice. The study provides proof‐of‐concept evidence for a potential of aBL to decontaminate PLTs during storage.

show abstract

Section: Discussionmentioning

confidence: 84%

Antimicrobial blue light for decontamination of platelets during storage

Lü

et al. 2019

Journal of Biophotonics

View full text Add to dashboard Cite

show abstract

“…At an exposure of 133 J/cm 2 , reductions in log 10 CFU were 6.27 for E. coli , 6.10 for S. aureus , 5.20 for P. aeruginosa , and 6.01 for S. pneumoniae . In another study from the same group of authors, the investigators found that β-lactam-resistant E. coli , which is resistant to penicillins, cephamycin, and carbapenems, is sensitive to aBL inactivation (Rhodes et al, 2016). Over 6-log 10 CFU reduction of the β-lactam-resistant E. coli strain on agar plates was achieved after an exposure of 68 J/cm 2 aBL.…”

Section: Efficacy Of Antimicrobial Blue Light Inactivation Of Pathmentioning

confidence: 99%

Antimicrobial blue light inactivation of pathogenic microbes: State of the art

Wang

et al. 2017

Drug Resistance Updates

223

192

View full text Add to dashboard Cite

As an innovative non-antibiotic approach, antimicrobial blue light in the spectrum of 400–470 nm has demonstrated its intrinsic antimicrobial properties resulting from the presence of endogenous photosensitizing chromophores in pathogenic microbes and, subsequently, its promise as a counteracter of antibiotic resistance. Since we published our last review of antimicrobial blue light in 2012, there have been a substantial number of new studies reported in this area. Here we provide an updated overview of the findings from the new studies over the past 5 years, including the efficacy of antimicrobial blue light inactivation of different microbes, its mechanism of action, synergism of antimicrobial blue light with other angents, its effect on host cells and tissues, the potential development of resistance to antimicrobial blue light by microbes, and a novel interstitial delivery approach of antimicrobial blue light. The potential new applications of antimicrobial blue light are also discussed.

show abstract

“…Visible light therapy is currently FDA approved for use for acne vulgaris, and research is being done to determine its role in treating SSI and device associated Gram-negative infections. An in vitro study evaluating the efficacy of violet 405nm light in treating ampicillin resistant Escherichia coli found an 81.7% reduction of bacterial growth with irradiance of 2.89 mW/cm 2 over 120 min (p < 0.001) [56]. Similarly, a review of both Gram-positive and Gram-negative bacteria susceptibility to violet light therapy between 380 and 480 nm found a 91% inactivation of Pseudomonas aeruginosa with 405 nm of VLT [57].…”

Section: Other Therapeutic Approachesmentioning

confidence: 99%

Trends, Epidemiology, and Management of Multi-Drug Resistant Gram-Negative Bacterial Infections in the Hospitalized Setting

2020

View full text Add to dashboard Cite

The increasing prevalence of antibiotic resistance is a threat to human health, particularly within vulnerable populations in the hospital and acute care settings. This leads to increasing healthcare costs, morbidity, and mortality. Bacteria rapidly evolve novel mechanisms of resistance and methods of antimicrobial evasion. Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter baumannii have all been identified as pathogens with particularly high rates of resistance to antibiotics, resulting in a reducing pool of available treatments for these organisms. Effectively combating this issue requires both preventative and reactive measures. Reducing the spread of resistant pathogens, as well as reducing the rate of evolution of resistance is complex. Such a task requires a more judicious use of antibiotics through a better understanding of infection epidemiology, resistance patterns, and guidelines for treatment. These goals can best be achieved through the implementation of antimicrobial stewardship programs and the development and introduction of new drugs capable of eradicating multi-drug resistant Gram-negative pathogens (MDR GNB). The purpose of this article is to review current trends in MDR Gram-negative bacterial infections in the hospitalized setting, as well as current guidelines for management. Finally, new and emerging antimicrobials, as well as future considerations for combating antibiotic resistance on a global scale are discussed.

show abstract

Violet 405 nm light: A novel therapeutic agent against β‐lactam‐resistant Escherichia coli

Cited by 14 publications

References 38 publications

Antimicrobial blue light for decontamination of platelets during storage

Antimicrobial blue light for decontamination of platelets during storage

Antimicrobial blue light inactivation of pathogenic microbes: State of the art

Trends, Epidemiology, and Management of Multi-Drug Resistant Gram-Negative Bacterial Infections in the Hospitalized Setting

Contact Info

Product

Resources

About